



Washington State Health Care Authority
Prescription Drug Program

626 8th Ave SE, Olympia, WA 98501 • 206-521-2029

<https://www.hca.wa.gov/about-hca/prescription-drug-program>

10/21/2022

Dear Interested Party,

Based on recommendations by the Washington State Pharmacy and Therapeutics Committee, the Health Care Authority, Uniform Medical Plan (UMP), and the Department of Labor & Industries (L&I) have named the following drugs as preferred in their respective therapeutic classes on the Washington State Preferred Drug List (PDL), effective January 1, 2023:

Asthma Biologics reviewed 2/16/2022			
Ingredient Name	Label Name of Preferred Product	L&I	UMP
dupilumab*	Dupixent [®] subcutaneous injection	Not participating	Yes
mepolizumab	Nucala [®] subcutaneous injection	Not participating	Yes
omalizumab	Xolair [®] subcutaneous injection	Not participating	Yes

*Dupilumab is categorized in the atopic dermatitis class, however, is also indicated for the treatment of asthma, eosinophilic esophagitis, and sinusitis with nasal polyps.

Atopic Dermatitis reviewed 2/16/2022			
Ingredient Name	Label Name of Preferred Product	L&I	UMP
dupilumab	Dupixent [®] subcutaneous injection	Not participating	Yes
tacrolimus	tacrolimus ointment	Not participating	Yes
pimecrolimus	pimecrolimus cream	Not participating	Yes
upadacitinib*	Rinvoq [®] 24hr tablet	Not participating	Yes

The effect of this recommendation is to make Dupixent[®] preferred on the WA PDL.

* Upadacitinib is categorized under the TIMs class, however, is also indicated for the treatment of atopic dermatitis.

Each agency will use the common PDL according to its benefit structure. You may view the current PDL on our [website](#).

If you have other questions or comments regarding this announcement, please contact Leta Evaskus at (206) 521-2029 or by email at leta.evaskus@hca.wa.gov.

Sincerely,

Donna Sullivan
Chief Pharmacy Officer
Clinical Quality and Care Transformation
Washington State Health Care Authority